Statistics

Total Visits

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r38

Select a period of time:

Number of views in the range

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r23

Views

Views
January 20251
February 20253
March 202516
April 20252
May 20251
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States6
Spain1
 

Top cities views

Views
Buffalo1
Council Bluffs1
Manchester1
Newark1
Pasadena1